Use of heat-treated clotting-factor concentrates in patients with haemophilia and a high exposure to HTLV-III.
In a group of 126 Australian patients with haemophilia, who were receiving lyophilized clotting-factor concentrates prepared from locally collected plasma, a high prevalence of antibody to human T-cell lymphotropic virus III (HTLV-III) was demonstrated in those with severe disease. Patients with moderate or mild disease had a much lower prevalence of HTLV-III antibody. After heat treatment of lyophilized factor VIII and factor IX concentrates (60 degrees C for 72 hours) to inactivate the virus, the losses of activity of an intermediate-purity and of a fibrinogen-poor factor VIII concentrate, and of the coagulant activity of a factor IX concentrate, were within acceptable limits. The solubility of the intermediate-purity factor VIII concentrate was markedly decreased; the fibrinogen-poor factor VIII concentrate and the factor IX concentrate were readily soluble. In-vivo recovery and survival of heated concentrates were equivalent to those of the unheated products, and they were effective in the treatment of spontaneous and traumatic haemorrhages.
McGrath
K M
KM
Thomas
K B
KB
Herrington
R W
RW
Turner
P J
PJ
Taylor
L
L
Ekert
H
H
Schiff
P
P
Gust
I D
ID
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000635:transmission; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D002648:Child; D017977:Deltaretrovirus / Q000276:immunology*; D005164:Factor IX / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D005169:Factor VIII / Q000009:adverse effects / Q000592:standards / Q000627:therapeutic use*; D006467:Hemophilia A / Q000276:immunology / Q000628:therapy*; D006358:Hot Temperature; D006801:Humans
D000914:Antibodies, Viral; D005169:Factor VIII; D005164:Factor IX